Key Points
- Andrew Callos sold 2,582 shares of Cytokinetics on March 9 at an average price of $60.72, reducing his stake by 5.12% to 47,858 shares (~$2.91M); this continues a pattern of recent insider selling that included much larger disposals earlier in the year.
- Cytokinetics is shifting to commercialization as revenue beat estimates ($17.76M) despite a slight EPS miss, the stock is up about 2.9% around $64, and analysts hold a generally bullish view with a consensus target of about $89.
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 2,582 shares of Cytokinetics stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $60.72, for a total transaction of $156,779.04. Following the sale, the executive vice president directly owned 47,858 shares in the company, valued at $2,905,937.76. The trade was a 5.12% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Andrew Callos also recently made the following trade(s):
- On Thursday, March 5th, Andrew Callos sold 26,000 shares of Cytokinetics stock. The stock was sold at an average price of $61.87, for a total transaction of $1,608,620.00.
- On Thursday, February 5th, Andrew Callos sold 15,000 shares of Cytokinetics stock. The stock was sold at an average price of $61.93, for a total transaction of $928,950.00.
- On Monday, February 2nd, Andrew Callos sold 886 shares of Cytokinetics stock. The shares were sold at an average price of $62.10, for a total value of $55,020.60.
- On Monday, January 5th, Andrew Callos sold 15,000 shares of Cytokinetics stock. The stock was sold at an average price of $60.28, for a total value of $904,200.00.
- On Friday, January 2nd, Andrew Callos sold 1,798 shares of Cytokinetics stock. The stock was sold at an average price of $62.62, for a total value of $112,590.76.
- On Monday, December 29th, Andrew Callos sold 1,809 shares of Cytokinetics stock. The shares were sold at an average price of $62.44, for a total value of $112,953.96.
Cytokinetics Stock Up 2.9%
NASDAQ CYTK opened at $64.20 on Wednesday. Cytokinetics, Incorporated has a twelve month low of $29.31 and a twelve month high of $70.98. The firm has a market capitalization of $7.91 billion, a PE ratio of -9.83 and a beta of 0.56. The stock's 50 day moving average is $64.02 and its 200 day moving average is $60.08.
Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its quarterly earnings data on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.48) by ($0.02). The business had revenue of $17.76 million during the quarter, compared to analyst estimates of $8.02 million. The company's quarterly revenue was up 4.9% compared to the same quarter last year. During the same period last year, the business posted ($1.26) EPS. On average, research analysts anticipate that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.
Wall Street Analyst Weigh In
Several research firms recently weighed in on CYTK. HC Wainwright upped their price target on Cytokinetics from $120.00 to $136.00 and gave the stock a "buy" rating in a research note on Monday, December 22nd. Bank of America restated a "neutral" rating on shares of Cytokinetics in a report on Wednesday, February 25th. UBS Group upped their price target on shares of Cytokinetics from $61.00 to $69.00 and gave the stock a "neutral" rating in a research note on Friday. B. Riley Financial increased their price objective on shares of Cytokinetics from $90.00 to $108.00 and gave the company a "buy" rating in a research report on Wednesday, January 21st. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Cytokinetics in a research note on Wednesday, January 21st. Seventeen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $89.00.
Get Our Latest Stock Analysis on CYTK
Key Stories Impacting Cytokinetics
Here are the key news stories impacting Cytokinetics this week:
- Positive Sentiment: Earnings/Investor call framed a “high‑stakes” commercial launch as Cytokinetics shifts from development to commercialization — investors view successful market uptake as material revenue upside. Cytokinetics Earnings Call Marks High-Stakes Launch Phase
- Positive Sentiment: An insider exercised stock options worth roughly $920k+ concurrent with the drug hitting the market — commonly interpreted as insiders monetizing launch-related value and confidence that commercialization is underway. Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market
- Positive Sentiment: Recent analyst activity is constructive — multiple firms have raised price targets and maintained buy/outperform stances, leaving a consensus target (~$89) well above the current trading range, supporting bullish expectations. Analyst Coverage Summary
- Neutral Sentiment: Reported short‑interest for early March shows “0” shares — likely a data error or placeholder rather than a real change in short positioning; treat this as non-informative until clarified.
- Negative Sentiment: Insider sales on March 9: CEO Robert Blum sold 7,931 shares at an average $60.72 (~$481.6k), reducing his stake ~1.98%; EVP Fady I. Malik sold 2,907 shares and EVP Andrew Callos sold 2,582 shares at the same price. While holdings remain substantial, these disclosures can be read as near-term profit-taking around the launch. SEC filings: CEO Form 4 (CEO Form 4), Malik Form 4 (Malik Form 4), Callos Form 4 (Callos Form 4).
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in CYTK. Bank of Montreal Can lifted its position in Cytokinetics by 1.2% during the fourth quarter. Bank of Montreal Can now owns 13,292 shares of the biopharmaceutical company's stock valued at $845,000 after purchasing an additional 160 shares during the period. Kennedy Capital Management LLC grew its position in Cytokinetics by 1.2% in the 4th quarter. Kennedy Capital Management LLC now owns 13,183 shares of the biopharmaceutical company's stock worth $838,000 after purchasing an additional 162 shares during the period. UMB Bank n.a. raised its stake in Cytokinetics by 10.6% during the 3rd quarter. UMB Bank n.a. now owns 1,762 shares of the biopharmaceutical company's stock valued at $97,000 after buying an additional 169 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in Cytokinetics by 46.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company's stock valued at $35,000 after buying an additional 171 shares during the last quarter. Finally, Vident Advisory LLC lifted its holdings in shares of Cytokinetics by 1.4% during the 4th quarter. Vident Advisory LLC now owns 16,455 shares of the biopharmaceutical company's stock valued at $1,046,000 after buying an additional 234 shares during the period.
Cytokinetics Company Profile
(
Get Free Report)
Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.
The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
